Peptides are coming
FDA Panel Votes to Restore Peptide Access — Here's What's Coming to Monday Medical
What Just Happened
On July 23 and 24, 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) convened a two-day meeting to formally evaluate whether seven peptides previously removed from compounding pharmacy access should be restored to the agency's 503A bulks list.
The 503A list is the regulatory framework that allows licensed compounding pharmacies — like those Monday Medical works with — to legally prepare and prescribe certain compounds to patients. In 2023, the FDA removed 19 peptides from this list, effectively halting access to many therapies that functional and longevity medicine providers had used for years.
Why it matters: The 503A bulks list isn't just administrative paperwork. If a compound isn't on the list, licensed compounding pharmacies cannot legally prepare it for patient use — regardless of the science behind it. Getting these peptides back on the list is what makes them accessible through clinics like Monday Medical.
The July 23–24 meeting marks the first formal step in a phased review process. The committee heard evidence, public testimony, and scientific data on seven compounds. A second meeting — to be held before the end of February 2027 — will address five additional peptides.
Why This Is Happening Now
The push for broader peptide access gained new momentum in early 2026, when HHS Secretary Robert F. Kennedy Jr. publicly called for re-examining peptide restrictions, citing patient demand and emerging research. While the policy machinery moves deliberately, the PCAC meeting represents the regulatory process working as intended — evaluating the evidence and making a formal recommendation.
Important distinction: The PCAC meeting is an advisory review — not a final approval. The committee's recommendations go back to the FDA, which then makes a final determination on whether to restore each compound to the 503A list. Monday Medical is monitoring this process closely and will notify patients as soon as confirmed approvals are announced.
This is meaningful progress. Prior to this meeting, there was no formal review pathway underway. The fact that the FDA convened this panel — and has already scheduled a follow-up — signals genuine regulatory movement, not just political noise.
What This Means for Peptide Therapy at Monday Medical
Monday Medical currently offers GHK-Cu and Oral BPC-157 — two of the compounds that remained accessible through compliant pathways. As new compounds are formally cleared through the 503A review process, we intend to make them available to patients as quickly as possible.
The 6 Peptides Under Review
The FDA's advisory committee reviewed the following compounds at the July 23–24 meeting, each evaluated based on available safety data and proposed clinical applications:
Important: These peptides are under advisory review — not yet formally cleared. The PCAC recommendation goes back to the FDA for a final determination before compounding pharmacies can legally prepare them for patients. Monday Medical will notify patients immediately upon formal clearance of each compound.
The Bigger Picture for Longevity Medicine
Peptide therapy sits at the intersection of precision medicine and evidence-based longevity optimization. These are not fringe compounds — many have decades of research behind them in areas ranging from growth hormone secretion to tissue healing to immune modulation. The 2023 restrictions were a regulatory setback, not a scientific verdict.
At Monday Medical, our approach to peptide therapy has always been the same: stay within compliant prescribing pathways, use only properly sourced compounds, and match each therapy to the individual patient's labs, goals, and health status. That won't change as new compounds come online.
Stay Ahead of the Curve
If you're a current Monday Medical patient and want to know whether you may be a candidate for upcoming peptide therapies, the best first step is a comprehensive hormone and metabolic panel — so we have a baseline picture of where you are today. If you're new to Monday Medical, a consultation is the place to start.
